Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Raj Murthy

Pain Medicine New York, NY Medical Doctor

NPI 1154776771 CMS profile 10116281

65 E 96Th St Apt 1B, New York, NY 10128

Open in the dashboard

General payments

$23,808

246 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Raj Murthy of New York, NY is reported in the CMS Open Payments database as having received $23,808 across 246 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,496 35
2024 General $10,421 81
2023 General $3,338 40
2022 General $4,191 54
2021 General $2,362 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raj Murthy
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Raj Murthy were reported at $3,496. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Raj Murthy Pain Medicine median Middle half National median
2019 $0 $409 $115–$1,311 $163
2020 $0 $214 $66–$666 $114
2021 $2,362 $299 $84–$899 $132
2022 $4,191 $335 $103–$1,149 $149
2023 $3,338 $376 $114–$1,228 $160
2024 $10,421 $387 $115–$1,173 $164
2025 $3,496 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $8,316 84 payments
  2. Boston Scientific Corporation $6,217 74 payments
  3. Medtronic, Inc. $2,306 23 payments
  4. Curonix LLC $2,196 10 payments
  5. MML US, Inc. $1,047 4 payments
  6. Nevro Corp. $1,000 13 payments
  7. Relievant Medsystems, Inc. $977 8 payments
  8. Orthofix Medical, Inc. $389 6 payments
  9. Painteq LLC $359 4 payments
  10. SI-BONE, Inc. $201 2 payments
  11. Other $800 18 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $12,070 43 payments
  2. Food and Beverage $11,444 202 payments
  3. Education $293 1 payment
Products named General payments · program years 2021–2025
  1. PROCLAIM Neuromodulation $4,912 31 payments
  2. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $2,196 10 payments
  3. SYNCHROMEDII $1,602 13 payments
  4. PROCLAIM Structural Heart $1,236 11 payments
  5. ReActiv8 $1,047 4 payments
  6. PROCLAIM Neuromodulation $1,027 22 payments
  7. Intracept Pain $1,001 9 payments
  8. Omnia $756 9 payments
  9. Intracept Pain $688 4 payments
  10. GENERAL PAIN MANAGEMENT $501 17 payments
  11. Other $6,372 101 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

667

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$6,419

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

0%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 348 $2,889
Methocarbamol Generic 60 $1,009
Diclofenac Sodium Generic 16 $461
Meloxicam Generic 115 $430
Duloxetine Hcl Generic 29 $346
Pregabalin Generic 13 $331
Oxycodone Hcl Generic 30 $309
Ibuprofen Generic 11 $218
Tizanidine Hcl Generic 18 $210
Cyclobenzaprine Hcl Generic 15 $148

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$90,991

Medicare's payments for the services billed

Medicare patients

207

Average age 73

Services billed

774

125 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 74%
Ischemic heart disease 39%
Diabetes 35%
Depression 28%
COPD 26%
Atrial fibrillation 20%
Chronic kidney disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

246 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record